OneOme and Genome.One team up to provide powerful genetic insights

Download Media Release

• Australia’s Genome.One and U.S.-based OneOme have partnered to provide insights into individuals’ genetic risk of disease and pharmacogenomic responses

• The offering is part of Australia’s first whole genome and health assessment service that provides new information to prevent or manage disease

• The service currently identifies genetic risk for 49 conditions and the body’s predicted response to 220 medications

06 July 2017 – Australia’s Genome.One and U.S.-based OneOme have partnered to provide genetic and pharmacogenomic information as part of a new personal health management service launched earlier this month that allows unprecedented insights into the current and future health of Australians.

This service includes genome sequencing provided by Genome.One and pharmacogenomic testing using OneOme’s RightMed test, which identifies how an individual’s DNA affects his or her response to certain medications. A comprehensive health assessment, offered in partnership with Sydney’s Life First, provides additional health and wellbeing information for a more comprehensive picture of an individual’s health.

Dr. Marcel Dinger, CEO of Genome.One, said that the partnership with OneOme is an important component of the company’s service. “Our service can detect a person’s increased genetic risk for more than 49 conditions across more than 230 genes, which helps healthcare professionals to offer advice on how to reduce identified risks. Understanding the body’s response to 220 medications adds important insights into how a condition can be managed.”

The RightMed pharmacogenomic test analyzes an individual’s DNA to better inform prescription decisions by predicting adverse drug reactions and drug effectiveness. It was co-developed and exclusively licensed from Mayo Clinic in the U.S. with the aim of bringing pharmacogenomics into routine clinical care.

Paul Owen, CEO of OneOme said that pharmacogenomics may unlock information about how specific drugs will affect you, based on your DNA. “Your body’s response to medication is determined by many factors, with the largest factor being your genetic makeup. A drug that’s effective for one person may have no effect for another person, or it may cause undesirable side effects. Information from our RightMed test can help healthcare providers make prescriptions more personal.”

“We believe in bringing the benefits of pharmacogenomics to everyone, and we’re thrilled to be partnering with Genome.One to make our service available to more people than ever before.”

The service is delivered by a team of health professionals who can offer expert interpretation to understand what the results mean as well as support and advice on what can be done to reduce identified risks.

Dr Dinger added: “Personal genomic information not only empowers individuals to take control of their health and potentially prevent disease, it can also optimise treatment in the clinic. This is why we believe that this service signals the beginning of a new era in understanding an individual’s health and the prevention and management of disease.”

- ENDS -

Media release issued on behalf of Genome.One by SenateSHJ

For further information please contact: 

Katy Thom 

SenateSHJ 02 9256 9716 / 0432 791 550 

Thomas Skinner

SenateSHJ 02 8257 0200 / 0451 147 528

About Genome.One

Genome.One ( is a pioneering health information company providing genetic answers to life’s biggest health questions through clinical whole genome sequencing. Genome.One aims to enhance the lives of patients, families and communities across the world. Genome.One is a wholly owned subsidiary of the Garvan Institute of Medical Research, Sydney, Australia.

In July 2016, Genome.One launched Australia’s first clinical whole genome testing service to provide diagnoses that can guide the care of individuals who are affected by genetic disease. 

About OneOme

The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit

Editor’s Note: Mayo Clinic has financial investment in the technology referenced in this news release. The revenue that Mayo Clinic will receive is used to support its not-for-profit mission in patient care, education and research.

For further information about OneOme, please contact:

Laura Smith

(612) 455-2369 

About the Garvan Institute of Medical Research

The Garvan Institute of Medical Research is one of Australia's largest medical research institutions and is at the forefront of next-generation genomic sequencing in Australia. Garvan’s main research areas are: cancer, diabetes and metabolism, genomics and epigenetics, immunology and inflammation, osteoporosis and bone biology, and neuroscience. Garvan’s mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health.

About the personal health management service: GoNavigate™ 

The health management service, GoNavigate™, is delivered by Genome.One in partnership with Life First at St Vincent’s Clinic, Sydney. This first-of-its-kind service can be accessed by those 18 years and over and includes a:

• whole genome testing service that provides an assessment of increased genetic risks of certain inherited conditions that could impact future health including: 31 cancers; 13 heart conditions; 5 other inherited conditions where monitoring and intervention can be of benefit. An analysis will be then received predicting an individual’s likely response to approximately 220 medications.

• comprehensive medical assessment in consultation with Life First doctors and exercise physiologists including head-to-toe physical examination, resting and stress ECG, full physiology review and analysis and extensive pathology testing. The GoNavigate service is available at a cost of $6400 (ex.GST). Five percent of Genome.One’s revenue from this service will be committed to supporting Australian families seeking diagnoses for rare and genetic conditions through the iHope network.

Further information can be found at